Compare Stocks: ARCT, NTLA, INBX, and SEPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.60 -1.4%	$8.95	$5.50 ▼ $24.17	$445.09M	2.48	600,424 shs	337,607 shs
INBX Inhibrx Biosciences	$113.61 -6.2%	$97.77	$26.19 ▼ $155.29	$1.67B	3.66	317,303 shs	1.26 million shs
NTLA Intellia Therapeutics	$12.72 -0.1%	$12.86	$7.95 ▼ $28.25	$1.78B	1.82	5.15 million shs	2.87 million shs
SEPN Septerna	$37.78 +2.8%	$37.48	$13.67 ▼ $51.10	$1.76B	2.3	358,926 shs	146,283 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+7.18%	+113.50%	+120.95%	-11.37%
INBX Inhibrx Biosciences	0.00%	-4.36%	+36.67%	+35.99%	+329.99%
NTLA Intellia Therapeutics	0.00%	+0.08%	+6.70%	-1.16%	+5.64%
SEPN Septerna	0.00%	-3.67%	-5.36%	+18.51%	+154.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.60 -1.4%	$8.95	$5.50 ▼ $24.17	$445.09M	2.48	600,424 shs	337,607 shs
INBX Inhibrx Biosciences	$113.61 -6.2%	$97.77	$26.19 ▼ $155.29	$1.67B	3.66	317,303 shs	1.26 million shs
NTLA Intellia Therapeutics	$12.72 -0.1%	$12.86	$7.95 ▼ $28.25	$1.78B	1.82	5.15 million shs	2.87 million shs
SEPN Septerna	$37.78 +2.8%	$37.48	$13.67 ▼ $51.10	$1.76B	2.3	358,926 shs	146,283 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+7.18%	+113.50%	+120.95%	-11.37%
INBX Inhibrx Biosciences	0.00%	-4.36%	+36.67%	+35.99%	+329.99%
NTLA Intellia Therapeutics	0.00%	+0.08%	+6.70%	-1.16%	+5.64%
SEPN Septerna	0.00%	-3.67%	-5.36%	+18.51%	+154.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$23.00	51.97% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	68.29% Upside
NTLA Intellia Therapeutics	2.35	Hold	$21.15	67.24% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	44.62% Upside

Current Analyst Ratings Breakdown

Latest ARCT, NTLA, INBX, and SEPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/27/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
8/24/2026	INBX Inhibrx Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$245.00
8/19/2026	SEPN Septerna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $48.00
8/13/2026	SEPN Septerna	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $62.00
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	5.24	N/A	N/A	$7.53 per share	2.01
INBX Inhibrx Biosciences	$1.30M	1,328.81	N/A	N/A	$0.55 per share	213.37
NTLA Intellia Therapeutics	$67.67M	26.19	N/A	N/A	$5.80 per share	2.18
SEPN Septerna	$45.95M	36.84	N/A	N/A	$8.53 per share	4.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)

Latest ARCT, NTLA, INBX, and SEPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
INBX Inhibrx Biosciences	12.58	5.07	5.07
NTLA Intellia Therapeutics	N/A	6.65	6.65
SEPN Septerna	N/A	4.99	4.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
INBX Inhibrx Biosciences	82.46%
NTLA Intellia Therapeutics	88.77%
SEPN Septerna	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
INBX Inhibrx Biosciences	18.26%
NTLA Intellia Therapeutics	3.50%
SEPN Septerna	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
INBX Inhibrx Biosciences	166	14.72 million	12.03 million	Optionable
NTLA Intellia Therapeutics	600	140.13 million	135.22 million	Optionable
SEPN Septerna	N/A	46.68 million	43.97 million	N/A

ARCT, NTLA, INBX, and SEPN Headlines

Recent News About These Companies

Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,333 Shares of Stock

September 4, 2026 | insidertrades.com

Septerna (NASDAQ:SEPN) SVP Sells $126,087.39 in Stock

September 3, 2026 | marketbeat.com

Septerna to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

BlackRock Inc. Purchases Shares of 1,932,088 Septerna, Inc. $SEPN

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Invests $43.72 Million in Septerna, Inc. $SEPN

August 28, 2026 | marketbeat.com

Primecap Management Co. CA Takes $39.10 Million Position in Septerna, Inc. $SEPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Purchases New Holdings in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Algert Global LLC Grows Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Septerna names Rajiv Patni as CMO

August 25, 2026 | msn.com

Septerna Appoints Rajiv Patni as Chief Medical Officer

August 25, 2026 | tipranks.com

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

August 25, 2026 | globenewswire.com

Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 22, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?

August 20, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

August 19, 2026 | marketbeat.com

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

August 19, 2026 | marketbeat.com

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

August 19, 2026 | marketbeat.com

37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC

August 15, 2026 | marketbeat.com

Major Insider Move Shakes Up Septerna, Inc. Shares

August 14, 2026 | tipranks.com

HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)

August 14, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares

August 14, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, NTLA, INBX, and SEPN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$15.60 -0.22 (-1.37%)

As of 02:23 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Inhibrx Biosciences NASDAQ:INBX

$113.61 -7.56 (-6.24%)

As of 02:24 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Intellia Therapeutics NASDAQ:NTLA

$12.72 -0.02 (-0.13%)

As of 02:23 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Septerna NASDAQ:SEPN

$37.78 +1.03 (+2.79%)

As of 02:23 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, NTLA, INBX, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, NTLA, INBX, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, NTLA, INBX, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, NTLA, INBX, and SEPN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Inhibrx Biosciences NASDAQ:INBX

Intellia Therapeutics NASDAQ:NTLA

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, NTLA, INBX, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, NTLA, INBX, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, NTLA, INBX, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, NTLA, INBX, and SEPN Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Inhibrx Biosciences NASDAQ:INBX

Intellia Therapeutics NASDAQ:NTLA

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools